NCT04035434 2025-10-24
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Phase 1/2 Terminated
Clinical Trials
32 trialsNCT04735471 2025-06-18
GLEAN-1
Adicet Therapeutics
Phase 1 Terminated
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT05296525 2025-03-25
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
Phase 1/2 Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT05588440 2024-12-05
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
NCT05720052 2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT04609579 2024-01-30
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
Phase 1 Terminated
NCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT02378038 2023-06-29
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT04045028 2023-04-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Genentech, Inc.
Phase 1 Terminated
NCT04804254 2023-02-03
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
Phase 1 Terminated
NCT03778073 2022-08-22
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
TG Therapeutics, Inc.
Phase 1 Terminated
NCT02361346 2022-08-18
MT-3724NHL001
Molecular Templates, Inc.
Phase 1/2 Terminated
NCT01744912 2022-05-11
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
TG Therapeutics, Inc.
Phase 1 Terminated
NCT02840110 2021-10-11
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Cogent Biosciences, Inc.
Terminated
NCT02186821 2021-04-08
SIGNATURE
Novartis
Phase 2 Terminated
NCT00521638 2021-02-18
Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Terminated
NCT02151903 2020-11-27
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Alopexx Oncology, LLC
Phase 1/2 Terminated
NCT02266147 2020-09-04
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT03670888 2020-01-09
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
JHL Biotech, Inc.
Phase 1 Terminated
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03379493 2019-02-04
Study of ET190L1 ARTEMISâ„¢ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT00486759 2017-07-25
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3 Terminated
NCT00768339 2011-07-13
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Aegera Therapeutics
Phase 1/2 Terminated
NCT00471367 2009-09-24
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
AstraZeneca
Phase 1 Terminated